Brokers Offer Predictions for Elutia FY2025 Earnings

Elutia Inc. (NASDAQ:ELUT) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Elutia in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($0.95) for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $10.00 target price on the stock. The consensus estimate for Elutia’s current full-year earnings is ($1.76) per share.

Elutia Stock Up 1.6 %

Shares of Elutia stock opened at $3.25 on Wednesday. Elutia has a 52 week low of $2.28 and a 52 week high of $5.24. The business has a 50 day moving average price of $3.90 and a 200-day moving average price of $3.83. The company has a market cap of $112.33 million, a PE ratio of -1.25 and a beta of 0.89.

Institutional Trading of Elutia

Several institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its position in shares of Elutia by 50.3% during the third quarter. Geode Capital Management LLC now owns 188,408 shares of the company’s stock valued at $718,000 after acquiring an additional 63,047 shares during the last quarter. Nantahala Capital Management LLC increased its position in shares of Elutia by 8.8% during the 2nd quarter. Nantahala Capital Management LLC now owns 1,795,697 shares of the company’s stock valued at $8,907,000 after purchasing an additional 145,697 shares during the last quarter. Arcus Capital Partners LLC raised its stake in shares of Elutia by 100.0% during the 3rd quarter. Arcus Capital Partners LLC now owns 20,000 shares of the company’s stock worth $76,000 after purchasing an additional 10,000 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Elutia by 50.5% in the 2nd quarter. Renaissance Technologies LLC now owns 53,616 shares of the company’s stock worth $266,000 after buying an additional 18,000 shares during the last quarter. Finally, Perkins Capital Management Inc. grew its position in Elutia by 9.8% during the third quarter. Perkins Capital Management Inc. now owns 856,552 shares of the company’s stock valued at $3,263,000 after buying an additional 76,450 shares during the period. Institutional investors own 74.03% of the company’s stock.

Elutia Company Profile

Elutia Inc, a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation, wound care, and breast reconstruction in the United States. The company operates in three segments: Device Protection; Women's Health; and Cardiovascular. It offers CanGaroo Envelope, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators.